StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) stock

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$156.50−3.23 (-2.02%)

Close on Nov 17, 2026Market cap $20.96BP/E 8.1Yield –

Alnylam Pharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

No total debt figures for Alnylam Pharmaceuticals

Alnylam Pharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Alnylam Pharmaceuticals figures

See a number that looks wrong?